We compared this watch-and-wait approach to the standard early postoperative adjuvant oncological treatment using case matching for both grade 3 oligodendrogliomas, IDH-mutant and 1p/19q-codeleted and astrocytomas, IDH-mutant. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).